Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
disorder : (in medicine) A condition where the body does not work appropriately, leading to what might be viewed as an illness
clinician determines final eligibility Who shouldn't apply: Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, history of pancreatitis, certain severe GI or kidney conditions, pregnancy, or breastfeeding - clinician screens at intake FDA regulatory status as of June 2026: Active enforcement and regulatory change ongoing
There is currently no direct clinical evidence specifically examining whether GLP-1 receptor agonists improve subjective brain fog symptoms in humans
& Henry, L
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes and, more recently, for weight loss
